Concord Biotech Limited

Equities

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. 06:00:01 2024-05-16 am EDT 5-day change 1st Jan Change
1,462 INR -1.71% Intraday chart for Concord Biotech Limited -2.62% -0.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Concord Biotech Limited(BSE:543960) added to S&P Global BMI Index CI
Concord Biotech's API Plant Gets GMP Certificate from Brazilian Health Regulator MT
Concord Biotech Limited Receives Certificate from Brazilian Health Regulatory Agency CI
India's Nifty 50 set to hit record high at open, surfing global rally RE
Jefferies Adjusts Concord Biotech’s Price Target to INR1,410 From INR1,440, Keeps at Hold MT
Certain Equity Shares of Concord Biotech Limited are subject to a Lock-Up Agreement Ending on 11-FEB-2024. CI
Concord Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jefferies Downgrades Concord Biotech to Hold From Buy, Adjusts Price Target to INR1,300 From INR1,260 MT
India's Cello World surges 29% on listing at $2.1 bln valuation RE
Indian cookware maker Cello World's IPO garners strong response RE
India's IRM Energy slides 11% in debut trade at over $200 million valuation RE
India's JSW Infrastructure jump 20% in pre-open trading debut RE
Concord Biotech Limited Announces Resignation of Utpal Hemendra Sheth as Independent Director CI
India's JSW Infrastructure receives bids worth $7.3 billion in IPO RE
Quadria Capital aims to raise up to $1 billion for new Asia healthcare fund RE
Concord Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
India's Aeroflex Industries soars over 81% in debut trade RE
Concord Biotech Limited Announces Resignation of Anil Katyal as Independent Director CI
US FDA Clears Concord Biotech's Manufacturing Plant in Gujarat, India MT
Concord Biotech Limited Announces Cessation of Amit Varma as Non-Executive Non-Independent Director CI
Concord Biotech Limited has completed an IPO in the amount of INR 15.505208 billion. CI
Chart Concord Biotech Limited
More charts
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,487 INR
Average target price
1,597 INR
Spread / Average Target
+7.36%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock
  4. News Concord Biotech Limited
  5. Jefferies Downgrades Concord Biotech to Hold From Buy, Adjusts Price Target to INR1,300 From INR1,260
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW